Skip to main content
. 2023 Jun 2;12:52. doi: 10.1186/s40164-023-00405-2

Table 2.

Mechanism and clinical trial phase of drugs against EZH2

Mechanism of action Name Specific for EZH2 Status Ref
SAH hydrolase inhibitors DZnep No Pre-clinical [92]
SAM-competitive inhibitors Tazemetostat Yes Phase II [93]

GSK126

(GSK2816126)

Yes Phase I [94]
SHR2554 Yes Phase I [76]
Interfering the interaction between EZH2 and EED

EED226

(MAK683)

Yes Phase I [77]
Promoting EZH2 degradation Sorafenib No FDA approval [79]